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Trends in esophageal cancer incidence by histology, United States, 1998–2003
Katrina F. Trivers*, Susan A. Sabatino and Sherri L. Stewart
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion,
Centers for Disease Control and Prevention, Atlanta, GA
Esophageal adenocarcinoma rates may be increasing, whereas,
squamous cell carcinoma rates appear to be decreasing in the
United States. Previous population-based research on esophageal
cancer has only covered up to 68% of the country. Additional,
updated research on a larger percentage of the country is needed
to describe racial, ethnic and regional trends in histologic subtypes
of esophageal cancer. Invasive esophageal cancer cases diagnosed
between 1998 and 2003 (n 5 65,926), collected by the National
Program of Cancer Registries or the Surveillance, Epidemiology,
and End Results program, were included. These data cover 83%
of the US population. Esophageal squamous cell carcinoma inci-
dence fell by 3.6%/year, whereas esophageal adenocarcinoma
increased by 2.1%/year. Squamous cell carcinoma rates decreased
among both sexes in most racial or ethnic groups, whereas adeno-
carcinoma rates increased primarily among white or non-His-
panic men. Except for white or non-Hispanic men, squamous cell
carcinoma rates were similar to, or greater than, adenocarcinoma
rates for men and women of all other races and ethnicities. The
largest decrease in squamous cell carcinoma rates occurred in the
West census region, which also exhibited no increase in adenocar-
cinoma rates. The rate of regional and distant-staged adenocarci-
nomas increased, while rates for local-staged adenocarcinoma
remained stable. This is the first article to characterize esophageal
cancer trends using data covering the majority of the US. Substan-
tial racial, ethnic and regional variation in esophageal cancer is
present in the US. Our work may inform interventions related to
tobacco and alcohol use, and overweight/obesity prevention, and
provide avenues for further research.
Published 2008 Wiley-Liss, Inc. This article is a US Government work
and, as such, is in the public domain in the United States of America.
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Little is known about the incidence of histologic subtypes of
esophageal cancer at the national level. Esophageal cancer is rela-
tively rare in the United States with 15,560 cases and 13,940
deaths expected to have occurred in 2007.1 However, rates of
esophageal adenocarcinoma increased dramatically between the
1970s and 1990s, particularly among white men, with a reported
rate of increase (>350%) greater than for any other cancer.2,3
Racial and ethnic,2–11 and geographic12 differences in incidence
have been observed, as well as differences by tumor stage.8,13
Nonetheless, few reports on esophageal cancer have included
recent incidence and trend data2–13; no reports have published
race- and sex-specific esophageal cancer trend estimates using
data since 1998. Continued updates on esophageal cancer rates
and trends at the national level are warranted given associations
between esophageal adenocarcinoma and elevated body mass
index14 and gastroesophageal reflux disease,15 both of which have
increased over the past few decades.16,17 Furthermore, previous
studies2–13 have only captured up to 68% of the population with
limited geographic diversity, limiting the ability to monitor
national and regional trends in esophageal cancer incidence. In
datasets with greater population coverage, such as the National
Program of Cancer Registries (NPCR), evidence suggests that
rates for tobacco-related cancers, including esophageal cancer, are
higher than in the Surveillance, Epidemiology and End Results
(SEER) program,18 possibly due to the inclusion of states with
higher tobacco use in the former. Therefore, further research with
such an expanded dataset covering a greater proportion of the US
will allow for a more complete characterization of esophageal can-
cer incidence in the US, as was recently reported for Europe.19
The greater number of cases will also enable examination of
rates and trends among smaller racial and ethnic groups, such as
American Indian/Alaskan Natives (AI/AN) and Asian and Pacific
Islanders (API) that have not been adequately studied.
The aim of our study was to fully characterize the incidence and
trends of histologic subtypes of esophageal cancer by race, ethnic-
ity, sex, geographic region and tumor characteristics (e.g., stage,
grade) in the United States between 1998 and 2003. To date, this is
the largest population-based nationwide study of esophageal cancer,
based on data used to publish official national cancer statistics. Data
in this analysis included >65,000 cases of esophageal cancer and
covered 83% of the US population for these years. Whether rates of
esophageal adenocarcinoma have continued to increase and what
groups are disproportionately affected remain an important public
health concern and may inform appropriate interventions.
Material and Methods
Source population
This report is comprised of data on newly diagnosed primary
esophageal cancers from population-based statewide cancer regis-
tries participating in the Centers for Disease Control and Preven-
tion’s NPCR and/or the National Cancer Institute’s SEER pro-
gram.20,21 These are the 2 major sources of cancer surveillance data
in the US and in combination are used to publish official national
cancer statistics. Both sources use uniform methodologies for data
collection and reporting. Only data from statewide registries that
met strict high-quality standards22 for all years (1998–2003) are
included in this report. High-quality standards for all cancer sites
combined included 90% complete case ascertainment, 5% of
cases ascertained solely based on death certificates, 3% of cases
missing information on sex or age, 5% of cases missing informa-
tion on race and 97% of registry’s records passing a set of single-
and inter-field edits.22 Included registries were from Alabama,
Alaska, Arkansas, California, Colorado, Connecticut, Delaware, the
District of Columbia, Florida, Hawaii, Idaho, Illinois, Indiana,
Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michi-
gan, Minnesota, Missouri, Montana, Nebraska, New Jersey, New
Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode
Island, South Carolina, Texas, Utah, Vermont, Washington, West
Virginia and Wisconsin. All registries were established prior to
1997 and were required to submit data to CDC as of 1997; only
incident cases were reportable and included.22 Data were continu-
ously updated and monitored every year for quality and included all
incident cases in a given state for the time period analyzed.22 Data
from these registries covered 83% of the US population. Coverage
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varied by region, with data from the Northeast and Midwest cover-
ing approximately 98% of their respective populations, and from
the West and South covering 88 and 63%, respectively. There were
69,766 cases of invasive, primary esophageal cancer reported from
the previously listed registries, excluding lymphomas arising in the
esophagus. Microscopic confirmation was not available for 3,840
cases and these were excluded from all analyses, leaving 65,926
cases for use in our study.
Similar to procedures in previous studies2,3,12 esophageal can-
cers were categorized into the following histologies: squamous
cell carcinoma, adenocarcinoma and all others. Esophageal can-
cers were grouped using the morphology codes from the Interna-
tional Classification of Diseases for Oncology, Third Edition
(ICD-O-3).23 The codes for each group, as well as selected sub-
groups, are listed in Table I. Morphology codes for cases diag-
nosed between 1998 and 2000 were coded using the ICD-O, Sec-
ond Edition24 and subsequently converted to ICD-O-3 codes.25 No
morphology codes for esophageal cancer differed between the sec-
ond and third editions.23 Tumor stage was defined as SEER Sum-
mary Stage (local, confined to the esophagus; regional, invaded
adjacent tissues or spread to regional lymph nodes; or distant,
metastasized or with distant lymph node involvement).26 Starting
with 2001 diagnoses, Summary Stage 2000 criteria were used26
and earlier diagnoses used Summary Stage 1977 rules.27 The dif-
ferences between the 2 staging systems were minimal for esopha-
geal cancer.28
Race was directly coded from the medical record and catego-
rized as white, black, Asian or Pacific Islander (API), AI/AN or
unknown. To minimize the effects of racial misclassification of
AI/AN, the Indian Health Service (IHS) patient registration data-
base was used to link cancer registry data on a routine basis.29,30
IHS provides medical services to AI/AN who are members of fed-
erally recognized tribes only, which is estimated to be approxi-
mately 57% of the AI/AN population in the US.30 Up to 26% of
individuals that were not identified as AI/AN in the registry linked
to the IHS patient registration database and were reclassified as
AI/AN as a result of the linkage (personal communication, Me-
lissa A. Jim, IHS). Ethnicity was categorized as Hispanic or non-
Hispanic. Ethnicity information was augmented by the North
American Association of Central Cancer Registries Hispanic Iden-
tification Algorithm (NHIA), which utilizes birthplace, race and/or
surname information.31,32 Up to 36% of people were reclassified
from unknown to known ethnicity due to NHIA in an analysis of
registry data from 1997 to 2001.33 Race and ethnicity are not
mutually exclusive and categories are consistent with federal
guidelines for reporting race and ethnicity.22
Statistical analyses
Number of cases and age-adjusted incidence rates, along with
95% confidence intervals (CIs), are presented for the different his-
tologic subtypes of esophageal cancer. Trends in incidence rates
over time were analyzed by examining annual percentage change
(APC) with 95% CIs over the 6-year period. Statistically signifi-
cant (p < 0.05) APCs are highlighted throughout the text. How-
ever, nonsignificant results are also discussed when the results
appeared to be clinically meaningful. Rates are per 100,000 per-
sons and are age-adjusted to the 2000 US standard population in
5-year age groups. Results were suppressed for groups that
included <6 people to protect confidentiality as well as prevent
presentation of unstable estimates. APCs were suppressed if <6
cases were present in one or more years.34 SEER*Stat software
version 6.2.435 was used.
TABLE I – HISTOLOGIC SUBTYPES OF MICROSCOPICALLY CONFIRMED,
INVASIVE ESOPHAGEAL CANCER, UNITED STATES,1 1998–2003
Histologic type ICD-O-3 codes2 Count (%)
Squamous cell carcinoma 8050–8082 24,889 (38%)
Squamous cell carcinoma 8070 22,366
Squamous cell carcinoma, keratinizing 8071 1,928
Squamous cell carcinoma,
large cell, nonkeratinizing
8072 424
Squamous cell carcinoma, spindle cell 8074 60
Other 111
Adenocarcinoma 8140–8573 36,800 (56%)
Adenocarcinoma, NOS 8140 32,746
Adenocarcinoma, intestinal type 8144 217
Neuroendocrine carcinoma, NOS 8246 119
Adenocarcinoma with mixed subtypes 8255 51
Papillary adenocarcinoma 8260 194
Mucinous adenocarcinoma and
mucin-producing adenocarcinoma
8480–8481 1,306
Signet ring cell carcinoma 8490 1,416
Adenosquamous carcinoma 8560 551
Other 200
All others 8000–8046, 8083–8084,
8090–8130, 8574–8576, 8580–9581
4,237 (6%)
Cancer, NOS 8000 428
Carcinoma, NOS 8010 2,606
Large cell carcinoma 8012 174
Carcinoma, undifferentiated, NOS 8020 114
Small cell carcinoma 8041–8045 364
Nonsmall cell carcinoma 8046 98
Basaloid squamous cell carcinoma 8083 87
Malignant melanomas 8720, 8742, 8772 57
Leiomyosarcomas 8890, 8891, 8895 38
Other 271
Total 65,926
NOS, not otherwise specified.
1Data from registries meeting quality standards for all years, representing 83% of the U.S. popula-
tion.–2Codes from International Classification of Diseases for Oncology, 2nd edition, (ICD-O-2) were
used for patients diagnosed between 1998 and 2000 and subsequently converted to International Classifi-
cation of Diseases for Oncology, 3rd edition (ICD-O-3) codes. ICD-O-3 codes were used for patients
diagnosed for 20011.
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Results
The majority of esophageal cancers (56%) diagnosed between
1998 and 2003 were adenocarcinomas, most of which were not
further specified (Table I). The next largest groups of specified ad-
enocarcinoma subtypes included mucinous adenocarcinoma or
mucin-producing adenocarcinoma (3.5%) and signet ring cell car-
cinoma (3.8%). Tumors that could not be classified as either ade-
nocarcinoma or squamous cell carcinoma (‘‘all other histologies,’’
6%) were typically unspecified histologies (e.g. cancer, NOS; car-
cinoma, NOS).
Among those diagnosed with squamous cell carcinomas, 70%
were white, 26% were black and 3% were API (Table II). Adeno-
carcinomas were more frequently diagnosed among whites (97%).
About 65% of squamous cell carcinomas but 85% of adenocarci-
nomas were diagnosed among men. Adenocarcinomas were also
more likely to be diagnosed at distant stage (36%) and grades III/
IV (55%) than squamous cell carcinomas (29 and 46%, respec-
tively). The only variables with substantial missing data were
stage and grade (data not shown). Among squamous cell carci-
noma cases, 21.3 and 17.9% were missing stage and grade infor-
mation, respectively. The same percentages among adenocarcino-
mas were 16.3 and 15.8%.
Between 1998 and 2003, the overall age-adjusted rates of squa-
mous cell carcinoma and adenocarcinoma of the esophagus were
1.8 per 100,000 (95% CI 5 1.7, 1.8) and 2.6 per 100,000 (95% CI
5 2.6, 2.6), respectively (Table III). The rate of squamous cell
carcinoma fell by an average of 3.6% per year whereas rates of ad-
enocarcinoma of the esophagus rose by 2.1% per year. When
examining subtypes of adenocarcinomas, mucinous or mucin-pro-
ducing adenocarcinoma rates did not increase (data not shown),
but signet ring adenocarcinoma rates did increase (APC 5 8.9%,
95% CI5 1.0, 17.4).
Rates of both squamous cell carcinoma and adenocarcinoma
increased with age, particularly after 60 years of age (Table III).
The highest rates of squamous cell carcinoma were in the Northeast,
and adenocarcinoma rates were highest in the Midwest. Western
states exhibited both the greatest decrease in squamous cell carci-
noma rates and no increase in adenocarcinoma rates. The lack of
increase in adenocarcinoma in the Western region appeared to be
driven by decreases of 2.1 and 8.3% in 2 states. Results for the
entire sample were unchanged when these 2 states were excluded.
Increases in rates of adenocarcinomas with poor prognostic fac-
tors, including those with distant stage and poorly differentiated
grade, occurred between 1998 and 2003 whereas rates of local and
well-differentiated disease were stable over this period. Distant-
stage adenocarcinomas also tended to have poorly differentiated
grade, and occurred more frequently among black men and
women, younger men and women, and men (data not shown). For
both histologies, the percentage of patients with unknown stage
decreased over time (data not shown). Among adenocarcinomas,
18.5 and 14.8% had unknown stage in 1998 and 2003, respec-
tively; for squamous cell carcinoma, the corresponding percen-
tages were 23.3 and 19.8%.
Adenocarcinoma rates were higher for non-Hispanics than His-
panics (IR 5 2.7; 95% CI 5 2.7, 2.7 and IR 5 1.3; 95% CI 5 1.2,
1.4, respectively). Rates of adenocarcinoma did not increase
among Hispanics during the 6-year study period, although rates
for non-Hispanics did increase (APC 5 2.3; 95% CI 5 1.3, 2.4).
Among racial groups, the highest rate of adenocarcinoma was
among whites (IR 5 2.8; 95% CI 5 2.8, 2.9), followed by AI/AN
(IR 5 1.6; 95% CI 5 1.3, 1.9). API had the lowest rate of adeno-
carcinoma (IR 5 0.4; 95% CI 5 0.4, 0.5). In all racial groups, ad-
enocarcinoma rates appeared to increase over time; however, for
groups other than white persons (APC 5 2.2; 95% CI 5 1.0, 3.4),
CIs were wide and included zero. Rates of squamous cell carci-
TABLE II – DISTRIBUTION OF DEMOGRAPHIC, GEOGRAPHIC AND TUMOR CHARACTERISTICS BY HISTOLOGIC
SUBTYPES OF MICROSCOPICALLY CONFIRMED, INVASIVE ESOPHAGEAL CANCER, UNITED STATES,1 1998–2003
Squamous cell carcinoma n (%) Adenocarcinoma n (%) All others n (%)
Age, years
<45 551 (2.2) 1,353 (3.7) 129 (3.0)
45–59 5,353 (21.5) 8,947 (24.3) 815 (19.2)
60–74 11,248 (45.2) 15,687 (42.6) 1,780 (42.0)
751 7,737 (31.1) 10,813 (29.4) 1,513 (35.7)
Region1
Northeast 6,728 (27.0) 9,445 (25.7) 971 (22.9)
Midwest 6,409 (25.8) 11,561 (31.4) 1,150 (27.1)
South 7,251 (29.1) 8,696 (23.6) 1,315 (31.0)
West 4,501 (18.1) 7,098 (19.3) 801 (18.9)
Summary stage
Local 6,140 (31.4) 8,964 (29.1) 708 (25.5)
Regional 7,735 (39.5) 10,730 (34.9) 694 (25.0)
Distant 5,710 (29.2) 11,093 (36.0) 1,377 (49.6)
Grade
Well (I) 1,339 (6.6) 2,110 (6.8) 28 (1.2)
Moderate (II) 9,668 (47.3) 11,974 (38.7) 79 (3.3)
Poorly (III) 9,166 (44.9) 16,274 (52.5) 1,746 (73.0)
Undifferentiated (IV) 254 (1.2) 615 (2.0) 539 (22.5)
Ethnicity2
Non-Hispanic 23,423 (94.1) 35,571 (96.7) 3,997 (94.3)
Hispanic 1,466 (5.9) 1,229 (3.3) 240 (5.7)
Race2
White 17,351 (70.1) 35,313 (96.7) 3,636 (86.4)
Black 6,475 (26.2) 891 (2.4) 495 (11.8)
AI/AN 101 (0.4) 123 (0.3) 17 (0.4)
API 816 (3.3) 200 (0.5) 62 (1.5)
Sex
Men 16,097 (64.7) 31,116 (84.6) 3,042 (71.8)
Women 8,792 (35.3) 5,684 (15.5) 1,195 (28.2)
AI/AN, American Indian/Alaska Native; API, Asian or Pacific Islander; NPCR, National Program of
Cancer Registries; SEER, Surveillance, Epidemiology and End Results Program.
1Data from registries meeting quality standards for all years, representing 83% of the U.S. population
(population coverage by region: Northeast, 98%; Midwest, 98%; West, 88%; South, 63%).–2Race and
ethnicity are not mutually exclusive.
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noma were highest in blacks (IR 5 5.5; 95% CI 5 5.3, 5.6) and
similar in all other racial groups (IR between 1.3 and 1.8). Squa-
mous cell carcinoma rates decreased over time for all racial
groups, although the decrease was not statistically significant for
AI/AN. Compared to women, men had approximately 2.4 times
the rate of squamous cell carcinoma (IR for men 5 2.6; 95% CI 5
2.5, 2.6) and over 7 times the rate of adenocarcinoma (IR for men
5 5.0; 95% CI5 4.9, 5.1).
Substantial differences in incidence of histologic subtypes of
esophageal cancer were present for combinations of race, ethnicity
and sex (Table IV). Among black men and women, API men and
women and non-Hispanic and Hispanic women, the incidence of
squamous cell carcinoma was higher than that of adenocarcinoma.
Among black men and women, squamous cell carcinoma inci-
dence exceeded adenocarcinoma incidence by 6.6 and 9.3 times,
respectively. Squamous cell carcinoma and adenocarcinoma inci-
dence were similar among AI/AN men and women, white women
and Hispanic men. Adenocarcinoma incidence was greater than
squamous cell incidence only for white men and non-Hispanic
men. Squamous cell carcinoma rates decreased for all race, ethnic-
ity and sex combinations, although APCs were nonsignificant in
some groups (Table IV, Figs. 1 and 2). Except for black men and
Hispanic women, APC estimates for all race, ethnicity and sex
combinations exceeded 1.0 for adenocarcinoma, although CIs
were wide and many included zero (Table IV, Figs. 3 and 4).
Discussion
Using more recent nation-wide data from population-based can-
cer registries with substantially increased population coverage com-
pared to previous studies, we found that most groups defined by
race, ethnicity, sex and region showed increasing rates of adenocar-
TABLE III – AGE-ADJUSTED INCIDENCE RATES AND TRENDS OVER TIME OF HISTOLOGIC SUBTYPES OF MICROSCOPICALLY CONFIRMED, INVASIVE
ESOPHAGEAL CANCER, BY DEMOGRAPHIC, GEOGRAPHIC AND TUMOR CHARACTERISTICS, UNITED STATES,1 1998–2003
Squamous cell carcinoma Adenocarcinoma
IR2 (95% CI) APC3 (95% CI) IR2 (95% CI) APC3 (95% CI)
Overall 1.8 (1.7, 1.8) 23.6* (24.6,22.5) 2.6 (2.6, 2.6) 2.1* (1.0, 3.3)
Age, years
<45 0.1 (0.1, 0.1) 23.4 (28.7, 2.3) 0.2 (0.1, 0.2) 2.7 (22.4, 8.0)
45–59 2.0 (2.0, 2.1) 23.7* (25.4,21.9) 3.4 (3.4, 3.5) 1.8 (20.4, 4.0)
60–74 7.6 (7.5, 7.8) 24.1* (25.5,22.7) 10.7 (10.5, 10.8) 1.9* (0.2, 3.6)
751 9.0 (8.8, 9.2) 22.6* (23.9,21.3) 12.6 (12.4, 12.8) 2.7* (1.1, 4.3)
Region1
Northeast 2.0 (1.9, 2.0) 23.0* (24.2,21.9) 2.8 (2.7, 2.9) 3.5* (2.2, 4.9)
Midwest 1.7 (1.6, 1.7) 22.6* (25.8, 0.7) 3.0 (3, 3.1) 1.9 (0.0, 3.8)
South 1.9 (1.8, 1.9) 23.8* (25.6,21.9) 2.2 (2.2, 2.3) 2.7* (0.6, 4.8)
West 1.5 (1.5, 1.6) 25.3* (27.4,23.1) 2.4 (2.3, 2.4) 0.4 (22.8, 3.6)
Summary stage
Local 0.4 (0.4, 0.4) 26.9* (210.5,23.2) 0.6 (0.6, 0.6) 1.1 (21.7, 4.0)
Regional 0.5 (0.5, 0.6) 21.8* (22.5,21.0) 0.8 (0.7, 0.8) 3.3* (0.4, 6.2)
Distant 0.4 (0.4, 0.4) 0.1 (22.6, 2.9) 0.8 (0.8, 0.8) 4.3* (3.1, 5.5)
Grade
Well (I) 0.1 (0.1, 0.1) 25.5* (27.7,23.1) 0.1 (0.1, 0.2) 20.9 (22.6, 0.9)
Moderate (II) 0.7 (0.7, 0.7) 23.4* (24.6,22.1) 0.8 (0.8, 0.9) 1.5* (0.6, 2.4)
Poorly (III) 0.6 (0.6, 0.7) 23.8* (24.7,23.0) 1.2 (1.1, 1.2) 2.2* (0.4, 4.1)
Undifferentiated (IV) 0 (0, 0) 210.4 (223.2, 4.5) 0 (0, 0) 20.1 (26.5, 6.7)
AI/AN, American Indian/Alaska Native; API, Asian or Pacific Islander; CI, confidence interval.
1Data from registries meeting quality standards for all years, representing 83% of the U.S. population (population coverage by region: North-
east, 98%; Midwest, 98%; West, 88%; South, 63%).–2IR, incidence rate (per 100,000 and age-adjusted to the 2000 US Standard Popula-
tion).–3APC, annual percent change between 1998 and 2003.–*APC is statistically significantly (p < 0.05) different than zero.
TABLE IV – INCIDENCE RATES AND TRENDS OVER TIME OF MICROSCOPICALLY CONFIRMED, INVASIVE, SQUAMOUS CELL CARCINOMA AND ADENO-
CARCINOMA OF THE ESOPHAGUS BY RACE, ETHNICITY AND SEX, UNITED STATES,1 1998–2003
Squamous cell Adenocarcinoma
n (%) IR2 (95% CI) APC3 (95% CI) n (%) IR2 (95% CI) APC3 (95% CI)
Men4
White 10,749 (43.4) 2 (1.9, 2.0) 23.4* (24.7, 22.1) 29,967 (82.0) 5.4 (5.4, 5.5) 2.1* (1.0, 3.2)
Black 4,579 (18.5) 9.3 (9.0, 9.6) 25.2* (27.3, 23.2) 662 (1.8) 1.4 (1.3, 1.5) 0.4 (26.3, 7.5)
AI/AN 79 (0.3) 2.5 (1.9, 3.2) 27.3 (227.4, 18.4) 102 (0.3) 3.0 (2.4, 3.7) 12.0 (29.7, 38.9)
API 602 (2.4) 3.0 (2.7, 3.2) 210.4* (215.1, 25.4) 158 (0.4) 0.8 (0.7, 0.9) 4.9 (29.9, 22.1)
Women4
White 6,602 (26.7) 0.9 (0.9, 0.9) 23.0* (25.2, 20.7) 5,346 (14.6) 0.8 (0.7, 0.8) 1.6 (21.0, 4.3)
Black 1,896 (7.7) 2.8 (2.7, 2.9) 22.3 (25.3, 0.8) 229 (0.6) 0.3 (0.3, 0.4) 9.3 (21.2, 20.9)
AI/AN 22 (0.1) 0.5 (0.3, 0.8)  21 (0.1) 0.5 (0.3, 0.8) 
API 214 (0.9) 0.9 (0.7, 1) 26.7 (218.1, 6.3) 42 (0.1) 0.2 (0.1, 0.2) 
Men4
Non-Hispanic 15,036 (60.4) 2.6 (2.6, 2.6) 23.9* (24.5, 23.3) 30,113 (81.8) 5.2 (5.1, 5.3) 2.2* (1.2, 3.2)
Hispanic 1,061 (4.3) 2.6 (2.4, 2.8) 26.5* (28.8, 24.2) 1,003 (2.7) 2.4 (2.2, 2.6) 1.2 (23.0, 5.4)
Women4
Non-Hispanic 8,387 (33.7) 1.1 (1.1, 1.1) 22.7* (24.9, 20.4) 5,458 (14.8) 0.7 (0.7, 0.7) 2.1 (20.1, 4.2)
Hispanic 405 (1.6) 0.8 (0.7, 0.9) 23.3 (210.7, 4.7) 226 (0.6) 0.5 (0.4, 0.5) 26 (216.9, 6.2)
AI/AN, American Indian/Alaska Native; API, Asian or Pacific Islander; CI, confidence interval.
1Data from registries meeting quality standards for all years, representing 83% of the U.S. population.–2IR, incidence rate (per 100,000 and
age-adjusted to the 2000 US Standard Population).–3APC, annual percent change between 1998 and 2003.–4Race and ethnicity are not mutually
exclusive.–Statistic could not be calculated (<6 cases in 1 year).–*APC is statistically significantly (p < 0.05) different than zero.
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cinoma and decreasing rates of squamous cell carcinoma over time.
Previous studies have observed that squamous cell carcinoma rates
have declined or remained stable for studied racial and ethnic
groups.7–9 Our findings add that for many groups, squamous cell
carcinoma rates were continuing to fall as of 2003. Despite
decreases in squamous cell carcinoma incidence, many groups clas-
sified by sex, race and ethnicity exhibited higher rates of squamous
cell carcinoma than adenocarcinoma. This burden of squamous cell
carcinoma for many racial and ethnic groups underscores the need
for continued awareness and education about squamous cell carci-
noma, as well as interventions to reduce risk for developing disease.
The current study also provides updated national estimates of
incidence and trends for smaller, less studied subgroups such as
AI/AN and API, including sex-specific rates. AI/AN had the sec-
ond highest adenocarcinoma incidence of any racial group,
whereas API had the lowest adenocarcinoma incidence. Consistent
with our results among AI/AN persons, an earlier study of Alaska
Natives noted a high incidence of esophageal cancer (all histolo-
gies combined) compared to other races.36 Ours is the first study
to provide stable and reliable sex- and histology-specific rate and
trend estimates for the AI/AN population. Previous literature
among API10 and Asian Americans7 observed that squamous cell
carcinoma incidence was greater than adenocarcinoma incidence,
similar to our results.
Contrary to previous literature that indicated increases in adeno-
carcinoma for Hispanic men and women,8 our data suggest that
rates of adenocarcinoma did not increase for Hispanic women,
and may have only minimally increased for Hispanic men.
We did not observe a large increase in adenocarcinoma among
black men, as has been previously reported2–4,6,7; however, our
shorter time frame might have limited our ability to detect time
trends for some subgroups of adenocarcinoma patients. Addition-
ally, differences among studies may have occurred in part due to
temporal variation. Previous studies have observed a high inci-
dence of squamous cell carcinoma among black men.7–9,11
In the present study, Western residents had the largest decrease
in squamous cell carcinoma rates and no increase in adenocarci-
noma rates. This is the first study to examine incidence and trends
in esophageal cancer by census regions of the US, rather than rely-
ing on examination of noncontiguous registries. Geographic dif-
ferences in esophageal cancer incidence have been previously
reported,12 but previous literature has been limited by examination
of disparate areas, making inter-regional comparisons in previous
FIGURE 1 – Age-adjusted annual invasive esophageal squamous cell
carcinoma rates in males, by race and ethnicity, US*, 1998–2003.
FIGURE 2 – Age-adjusted annual invasive esophageal squamous cell
carcinoma rates in females, by race and ethnicity, US*, 1998–2003.
FIGURE 3 – Age-adjusted annual invasive esophageal adenocarci-
noma rates in males, by race and ethnicity, US*, 1998–2003.
FIGURE 4 – Age-adjusted annual invasive esophageal adenocarci-
noma rates in females, by race and ethnicyt, US*, 1998–2003.
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studies difficult. Further research is needed to identify reasons for
regional differences.
Importantly, the rate of regional and distant-stage adenocarci-
noma increased more rapidly than that of local-stage tumors, and,
for both histologies, rates of unstaged disease decreased. These
results are consistent with findings from a previous study of the
1988–1993 National Cancer Data Base.13 However, a study of
SEER data from 1973 through 1998 observed that the incidence of
Stage IV disease decreased.8 It is unclear whether the observed
increase in distant-stage adenocarcinoma in our data is real or if it
reflects more accurate staging over time; it is possible cases that
historically were classified as unstaged are now being correctly
classified as distant.
Our results indicate a smaller magnitude of increase of esopha-
geal adenocarcinoma (2.1% among white men) than previously
reported.2–5,7,8 Previous studies estimated that, between 1976 and
1987, the average annual rates of increase in adenocarcinoma
were 9.4% for white men, 9.8% for black men and 4.5% for white
women.2 Based on publicly available data from population-based
registries covering 9.5% of the country,37 the APC of invasive,
microscopically confirmed esophageal adenocarcinoma for white
men between 1985 and 1998 was 6.8% (95% CI5 5.8, 7.9). These
findings combined with our results may suggest an ongoing decel-
eration in adenocarcinoma rates. However, differences in popula-
tions covered by various data sources must be considered.
Modifiable risk factors for esophageal cancer may be amenable
to population-based interventions. Squamous cell carcinoma of
the esophagus is associated with tobacco use and alcohol con-
sumption,14,38 and these factors and low consumption of fruits and
vegetables may account for 89% of cases.39 Adenocarcinoma is
associated with tobacco use, gastroesophageal reflux disease and
elevated body mass index14,38 and approximately 79% of cases
may be attributed to these factors, or low consumption of fruits
and vegetables.39 Recent decreases in cigarette use, particularly
among men,40 have likely contributed to the decrease in squamous
cell carcinoma. However, esophageal adenocarcinoma risk
remains elevated after tobacco cessation,38 suggesting that
decreases in smoking-associated adenocarcinoma may take longer
to be observed. The prevalence of overweight increased from 56
to 65% between the periods 1988–1994 and 1999–2000, and obe-
sity prevalence increased from 8 to 13% during the same time
frame.17 These increases may have contributed to the increase in
esophageal adenocarcinoma. Multiple strategies to decrease
tobacco use and prevent overweight and obesity have been found
to be effective and summarized by the Guide to Community Pre-
ventive Services, which reviews and recommends community and
health care system interventions (www.thecommunitygui-
de.org).41,42 Combining surveillance research with effective com-
munity interventions may help reduce the burden of tobacco- and
obesity-associated cancers.
Limitations to our study may have influenced our results. No
risk factor information was available, so we were unable to exam-
ine the influence of risk factors such as tobacco and alcohol use,
and obesity on incidence trends. Even in this large dataset, some
groups of interest had small sample sizes. Also, the short time
frame may have limited our power to examine trends over time.
Data were largely based on medical records, thus some misclassi-
fication is possible, particularly for race and ethnicity. While data
for whites and blacks are typically reliable, cancer cases for AI/
AN, API and Hispanics may be underestimated,43,44 although the
IHS linkages and Hispanic identification algorithm likely reduced
such misclassification. In the South, the population covered by the
data in this report (63%) was lower than in other regions, and the
population not covered by the data may differ from the included
population. Reliable information is not available to adequately
compare included and excluded states for characteristics such as
socioeconomic status and race/ethnicity. Therefore, the magnitude
and direction of potential bias from missing data is unknown. De-
spite this limitation, our study included the largest population cov-
erage to date. Furthermore, there was no centralized pathology
review. However, although some variation exists among individual
pathologists, data quality studies have shown that histology data in
NPCR registries are 91% accurate.45 The percentage of unspecified
histology diagnoses, sometimes a measure of data quality in regis-
tries, was very low (on average, <5%). Furthermore, percentages
of individual esophageal histologies (adenocarcinoma and squa-
mous cell carcinoma) and of unknown stage and grade were
reported similarly across the majority of registries, including those
from NPCR registries and those funded only by SEER. Last, high
quality data standards pertain to all cancer cases combined and
may not specifically apply to esophageal cancers. However, quality
criteria are not likely to vary much by cancer site.45
This is the largest population-based study in the US to examine
incidence and trends in histologic subtypes of esophageal cancer,
and we were able to expand previous knowledge about ethnic,
racial and regional differences in esophageal cancer incidence.
The large sample size allowed estimation of sex-specific rates for
previously understudied groups such as AI/AN and API, as well as
comparisons by geographic region. The wide population coverage
of the data allowed for increased generalizability compared to pre-
vious studies.
Esophageal adenocarcinoma incidence increased by 2.1% per
year, whereas squamous cell carcinoma of the esophagus
decreased by 3.6% per year between 1998 and 2003. However,
squamous cell carcinoma rates were similar to, or greater than, ad-
enocarcinoma rates for men and women of all races and ethnic-
ities, except for white or non-Hispanic men. The rate of increase
for esophageal adenocarcinoma reported here is smaller than pre-
viously observed. Our results highlight the need for continued
monitoring of trends at the national level, particularly for esopha-
geal adenocarcinoma, and for determination of factors driving
trends. To the extent that changes are due to tobacco and alcohol
use and overweight and obesity, findings suggest that public health
interventions to address these factors may be warranted.
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